Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France Université de Strasbourg, Strasbourg, France.
Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL), Lyon, France.
Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10.
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.
HBV 感染是导致肝硬化和肝细胞癌的主要原因。尽管乙型肝炎病毒（HBV）感染可以通过疫苗接种得到有效预防，并且有治疗方法，但迄今为止，全球仍有超过 2.4 亿人慢性感染，尚无可靠的治愈方法。目前的治疗方法只能实现病毒抑制，大多数感染者需要终身治疗。在法国国家艾滋病和病毒性肝炎研究署（ANRS）“HBV 治愈”计划的框架内，2014 年 6 月在巴黎举行了一次科学研讨会，旨在确定 HBV 发病机制的最新进展和未解决的问题，并制定实现 HBV 治愈的协同战略。这篇综述总结了我们目前对导致病毒持续存在的 HBV 宿主相互作用的理解，以及克服这些障碍以最终解决慢性 HBV 感染治疗中未满足的医疗需求所面临的挑战。
